GSK has submitted an application for the world’s first malaria vaccine to the European Medicines Agency (EMA).
The vaccine candidate, RTS,S, is produced in yeast cells and targets the Plasmodium falciparum malaria parasite, most common in sub-Saharan Africa. It uses GSK’s proprietary AS01 adjuvant system, containing QS-21 Stimulon adjuvant licensed from Antigenics, a subsidiary of Agenus, as well as monophosphoryl lipid A (MPL) and liposomes.